ES2877513T3 - Péptidos CD31 mejorados - Google Patents

Péptidos CD31 mejorados Download PDF

Info

Publication number
ES2877513T3
ES2877513T3 ES13729753T ES13729753T ES2877513T3 ES 2877513 T3 ES2877513 T3 ES 2877513T3 ES 13729753 T ES13729753 T ES 13729753T ES 13729753 T ES13729753 T ES 13729753T ES 2877513 T3 ES2877513 T3 ES 2877513T3
Authority
ES
Spain
Prior art keywords
peptide
seq
amino acid
amino acids
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13729753T
Other languages
English (en)
Spanish (es)
Inventor
Giuseppina Caligiuri
Antonino Nicoletti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Assistance Publique Hopitaux de Paris APHP
Institut National de la Sante et de la Recherche Medicale INSERM
Universite Sorbonne Paris Nord
Universite Paris Cite
Original Assignee
Assistance Publique Hopitaux de Paris APHP
Institut National de la Sante et de la Recherche Medicale INSERM
Universite Sorbonne Paris Nord
Universite de Paris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assistance Publique Hopitaux de Paris APHP, Institut National de la Sante et de la Recherche Medicale INSERM, Universite Sorbonne Paris Nord, Universite de Paris filed Critical Assistance Publique Hopitaux de Paris APHP
Application granted granted Critical
Publication of ES2877513T3 publication Critical patent/ES2877513T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
ES13729753T 2012-06-19 2013-06-19 Péptidos CD31 mejorados Active ES2877513T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12305697 2012-06-19
PCT/EP2013/062806 WO2013190014A1 (en) 2012-06-19 2013-06-19 Improved cd31 peptides

Publications (1)

Publication Number Publication Date
ES2877513T3 true ES2877513T3 (es) 2021-11-17

Family

ID=48652100

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13729753T Active ES2877513T3 (es) 2012-06-19 2013-06-19 Péptidos CD31 mejorados

Country Status (11)

Country Link
US (1) US10815272B2 (enExample)
EP (1) EP2861241B1 (enExample)
JP (1) JP6357470B2 (enExample)
DK (1) DK2861241T3 (enExample)
ES (1) ES2877513T3 (enExample)
HR (1) HRP20211017T1 (enExample)
HU (1) HUE055593T2 (enExample)
PL (1) PL2861241T3 (enExample)
PT (1) PT2861241T (enExample)
SI (1) SI2861241T1 (enExample)
WO (1) WO2013190014A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109069586A (zh) * 2016-03-21 2018-12-21 国家健康与医学研究院 用于再灌注损伤的预防和/或治疗的cd31shed激动剂
JP7166512B2 (ja) * 2016-05-03 2022-11-08 インスティチュート ナショナル デ ラ サンテ エ デ ラ ルシェルシュ メディカル （インセルム） 炎症のイメージングのための分子標識としてのＣＤ３１ｓｈｅｄ
US20220001083A1 (en) * 2018-11-27 2022-01-06 Balt Extrusion Method for the modification of a device surface by grafting a cd31-derived peptide onto the surface of said device
WO2020109833A1 (en) 2018-11-27 2020-06-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for the modification of a substrate surface by grafting a peptide onto the surface of said substrate
WO2023099932A1 (en) * 2021-12-03 2023-06-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Cd31 mimetic coating for endovascular stent

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087331A (en) 1990-01-19 2000-07-11 The Blood Center Of Southeastern Wisconsin Therapeutic use of platelet-endothelial cell adhesion molecule-1 compositions
JP3914988B2 (ja) * 2003-08-06 2007-05-16 国立大学法人名古屋大学 細胞死誘導のためのペプチドおよび医薬
EP2313432B1 (en) * 2008-06-30 2017-09-13 Institut National de la Sante et de la Recherche Medicale (INSERM) Use of cd31 peptides in the treatment of thrombotic and autoimmune disorders
WO2013152919A1 (en) 2012-04-11 2013-10-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) Detection of platelet-derived shed cd31

Also Published As

Publication number Publication date
HRP20211017T1 (hr) 2021-10-01
SI2861241T1 (sl) 2021-11-30
JP2015521611A (ja) 2015-07-30
EP2861241A1 (en) 2015-04-22
PL2861241T3 (pl) 2021-10-25
US20150203536A1 (en) 2015-07-23
EP2861241B1 (en) 2021-04-28
DK2861241T3 (da) 2021-07-05
JP6357470B2 (ja) 2018-07-11
HUE055593T2 (hu) 2021-12-28
PT2861241T (pt) 2021-07-02
US10815272B2 (en) 2020-10-27
WO2013190014A1 (en) 2013-12-27

Similar Documents

Publication Publication Date Title
ES2515241T3 (es) Polipéptidos multímeros de HLA-G que incluyen al menos dos dominios alfa3 y usos farmacéuticos de los mismos
ES2709176T3 (es) Péptidos inmunogénicos y su uso en trastornos inmunitarios
ES2877513T3 (es) Péptidos CD31 mejorados
ES2626115T3 (es) Péptidos inmunogénicos y su uso en trasplante
ES2716870T3 (es) Composición para el tratamiento y prevención de lesión isquémica
ES2683844T3 (es) Proteína de fusión que comprende una interleucina 4 e interleucina 10
US10253085B2 (en) CD31 peptides for the treatment of thrombotic or autoimmune disorders
US10538558B2 (en) Inhibition of TCR signaling with peptide variants
ES2769778T3 (es) Composiciones inmunomoduladoras
CA2884121C (en) Inhibiting peptides derived from triggering receptor expressed on myeloid cells-1 (trem-1) trem-like transcript 1 (tlt-1) and uses thereof
CZ20031630A3 (cs) Peptidy a/nebo proteiny a jejich použití pro přípravu terapeutického a/nebo preventivního farmaceutického přípravku
US20210379146A1 (en) Method to restore or improve cognitive functions
ES2246915T3 (es) Composiciones para el tratamiento de anormalidades en filtraciones glomoleculares, de persistencia de canal arterial y de osteoporosis.
ES2526822T3 (es) Péptidos hsp y análogos para la modulación de respuestas inmunes mediante células presentadoras de antígeno
JP7037486B2 (ja) 医薬としてのヒト由来免疫抑制タンパク質およびペプチドの使用
JP2007500693A (ja) 移植片拒絶反応を予防するための合成ペプチドコポリマーを含む併用療法
ES2749073T3 (es) Un péptido donante aislado derivado de MHC y su uso
JP2019512520A (ja) 再灌流傷害の予防および／または治療に使用するためのＣＤ３１ｓｈｅｄアゴニスト
WO2022189659A1 (en) Trem-1 inhibitors for the treatment of marfan syndrome
RU2130317C1 (ru) Линейные или циклические пептиды, их применение, способ лечения
KR20160140147A (ko) 심장 허혈후 재관류 손상에 의한 심장 질환 치료 및 예방용 조성물
JPWO2005077971A1 (ja) ヘビ毒由来の血管内皮増殖因子（ｖｅｇｆ）様タンパク質のヘパリン結合部位より設計された新規なヘパリン結合能を有するペプチドとその用途
JPH06157332A (ja) 血管再建術後血管再狭窄及び動脈硬化の治療用医薬組成物